**Eligibility Criteria**

All patients must pass the following criteria in addition to the treatment specific criteria:

* Must be at least 18 years of age
* Patient or LAR must be able to give consent
* Laboratory confirmed diagnosis of SARS-COV-2
* Admitted to hospital for care
* **Investigational treatments cannot be given simultaneously**

|  |  |  |
| --- | --- | --- |
| **Expanded Access Program** | **Inclusion Criteria** | **Exclusion Criteria** |
| **Convalescent Plasma**  | 1. Severe disease **(at least 1)**
	1. **Dyspnea**
	2. RR ≥30/min
	3. O2 ≤93%
	4. Partial pressure of arterial O2 to fraction of inspired oxygen ration < 300
	5. Lung infiltrates < 50% within 24-48 hrs

**OR**1. Life-threatening disease **(at least 1)**
	1. Respiratory failure
	2. Septic shock
	3. Multiple organ dysfunction

**OR**1. Judged by provider to be at **high risk of progression**
 | None  |
| **Ruxolitinib**  | 1. 1 or more manifestations of cytokine storm (following are not exhaustive)
	1. Severe shortness of breath (RR > 24/min)
	2. SpO2 <90% on room air
	3. Need or invasive or noninvasive mechanical ventilation
	4. Acute respiratory distress syndrome
	5. Multiple organ failure
 | * Inadequate liver function
* Platelet count <50 x 109/L
* Underlying condition that would place the patient at a risk
* Previous allergic reaction to JAK inhibitors or excipients
* Concomitant use of any other JAK inhibitor
 |
| **Remdesivir** Only available at Kettering Medical Center location **Compassionate Use Request Available for pregnant women and children <18 at other KHN locations.**  | 1. **Requiring invasive mechanical ventilation**
2. ALT ≤ 5 X upper limit of normal
 | * **Multiorgan failure**
* Use of more than 1 pressor for septic shock (use of 1 pressor at low/medium doses for inotropic support due to use of sedation and paralytics while on vent is allowed
* Renal failure (eGFR<30)
 |

**If interested in putting your patient on one of these treatments, please contact Allison Dymacek, Manager, Research Operations**